FDA accepts Roche unit Genentech vamikibart filing for uveitic macular edema treatment
The FDA accepted Genentech’s filing for vamikibart to treat uveitic macular edema and set a target decision date of July 2027. Regulatory filings were also accepted in the EU, China and Japan.
1. Regulatory filings accepted
The FDA accepted Roche unit Genentech’s biologics license application for vamikibart to treat uveitic macular edema, with a target decision date of July 2027. Regulatory filings were also accepted in the EU, China and Japan.
